Baird raised the firm’s price target on Revvity (RVTY) to $138 from $136 and keeps an Outperform rating on the shares. The firm said they posted 3Q revenue/EPS ahead of consensus, with mixed revenue performance. The company continued to message stability in pharma/biotech, though customer spending on instruments remains constrained, particularly in China.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity Reports Strong Q3 Growth and New Share Buyback
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal
- Revvity raises FY24 adjusted EPS view to $4.83-$4.87 from $4.70-$4.80
- Revvity reports Q3 adjusted EPS $1.28, consensus $1.12
- Revvity announces $1B share repurchase program